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Ductular reactionMyoﬁbroblasts combine the matrix-producing functions of ﬁbroblasts and the contractile properties of
smooth muscle cells. They are the main effectors of ﬁbrosis in all tissues and make a major contribution to
other aspects of the wound healing response, including regeneration and angiogenesis. They display the de
novo expression of α-smooth muscle actin. Myoﬁbroblasts, which are absent from the normal liver, are de-
rived from two major sources: hepatic stellate cells (HSCs) and portal mesenchymal cells in the injured
liver. Reliable markers for distinguishing between the two subpopulations at the myoﬁbroblast stage are cur-
rently lacking, but there is evidence to suggest that both myoﬁbroblast cell types, each exposed to a particular
microenvironment (e.g. hypoxia for HSC-MFs, ductular reaction for portal mesenchymal cell-derived
myoﬁbroblasts (PMFs)), expand and exert specialist functions, in scarring and inﬂammation for PMFs, and
in vasoregulation and hepatocellular healing for HSC-MFs. Angiogenesis is a major mechanism by which
myoﬁbroblasts contribute to the progression of ﬁbrosis in liver disease. It has been clearly demonstrated
that liver ﬁbrosis can regress, and this process involves a deactivation of myoﬁbroblasts, although probably
not to a fully quiescent phenotype. This article is part of a Special Issue entitled: Fibrosis: Translation of
basic research to human disease.
© 2013 Elsevier B.V. All rights reserved.1. Introduction
Myoﬁbroblasts are the main effectors of ﬁbrosis in all tissues. They
also make a major contribution to other aspects of the wound healing
response, including regeneration, inﬂammation, angiogenesis, normal
tissue repair after acute injury and to the stromal reaction in
tumors. They combine phenotypic features of ﬁbroblasts, such as
the production of extracellular matrix, with the contractile functions
of the smooth muscle cells involved in tissue architecture distortion.
Myoﬁbroblasts may be deﬁned as cells that develop contractile force
and stress ﬁbers, de novo, and in vivo [1]. The most widely used and
accessible marker of these cells is the de novo expression of
α-smooth muscle actin (α-SMA), although this is not an absolute
requirement for the identiﬁcation of a cell as a myoﬁbroblast. Other
markers of myoﬁbroblasts (endosialin, P311, integrin α11β1,
osteopontin, periostin) have been proposed, but all were identiﬁedC, hepatic stellate cell; PMF,
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l rights reserved.in speciﬁc conditions, and it remains unclear whether they could
serve as general markers [1]. The precursors of myoﬁbroblasts have
also yet to be identiﬁed. In most tissues, myoﬁbroblasts are thought to
originate from resident ﬁbroblasts, but they may also be derived from
other cell types, mostly ofmesenchymal origin, such as vascular smooth
muscle cells, pericytes and adipocytes. There is also evidence to suggest
that myoﬁbroblasts may be derived from circulating ﬁbrocytes or
resident epithelial cells, through epithelial-to-mesenchymal transition,
although recent studies argue against a signiﬁcant contribution of
these mechanisms to ﬁbrosis. In addition, resident ﬁbroblasts are
themselves heterogeneous and may even include antiﬁbrotic subpopu-
lations, such as lung Thy-1-expressing ﬁbroblasts [2].
2. Origins of myoﬁbroblasts in liver ﬁbrosis
Myoﬁbroblasts are absent from the normal liver, but they accumulate
at sites of injury, in patients with chronic liver diseases. They are the
major source of extracellular matrix constituents in the injured
liver, as clearly demonstrated by clinical and experimental studies.
However, although myoﬁbroblasts appear to be necessary for the
development of ﬁbrosis, they may not be sufﬁcient. For example, in
scleroderma [1] and focal nodular hyperplasia (unpublished
personal observation), the liver may contain large numbers of
myoﬁbroblastic cells without signiﬁcant ﬁbrosis. In the liver, as in
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During liver development, the septum transversum-derived meso-
thelium, which signals to induce hepatogenesis from the foregut
endoderm, gives rise to sinusoidal pericytes, called hepatic stellate
cells (HSCs), and perivascular mesenchymal cells, including portal
ﬁbroblasts, smooth muscle cells and ﬁbroblasts around the central
veins [3]. All these cells therefore have a common mesodermal
origin, different from that of sinusoidal endothelial cells, Kupffer
cells and hepatoblasts. It is now more than 35 years since the initial
demonstration by Hans Popper and coworkers that transitional cells
with the morphologic characteristics of vitamin A-containing cells
(i.e. HSCs) and ﬁbroblasts, overproduce ﬁbrillar collagen in rats
with carbon tetrachloride-induced liver injury [4]. The paradigm of
hepatic stellate cell (HSC) activation giving rise to myoﬁbroblasts
has since dominated the focus of research on liver ﬁbrosis [5]. HSC
was the ﬁrst major cell type in the liver to be identiﬁed as a
prominent source of collagen production in the injured liver
[6], and to be shown to acquire a myoﬁbroblastic phenotype in
culture, with the ability to overproduce extracellular matrix, to
contract and to undergo chemoattraction [7–10]. The factors and
mechanisms triggering the myoﬁbroblastic differentiation of hepatic
stellate cells have been reviewed extensively elsewhere [5]. They
include biological (e.g. lipopolysaccharide) [11], physicochemical
(e.g. hypoxia) [12] and mechanical (e.g. substrate stiffness) [13]
stimuli. There is now both in vitro and in vivo evidence for the
existence of more than one origin of liver myoﬁbroblasts. In prepara-
tions of cells isolated from the liver, HSCs are recognized by the
ﬂuorescence of their retinoid droplets under UV excitation at a
wavelength of 328 nm. Culture studies have clearly demonstrated
that other liver cell types, without ﬂuorescent retinoid droplets,
can give rise to myoﬁbroblasts [14,15]. In situ ultrastructural studies
have shown that ﬁbroblasts reside in the portal mesenchyme and
accumulate, with ﬁbrosis, around bile ducts in bile duct-ligated rats
[16], precisely in the zones in which α-SMA can be detected
[15]. Moreover, immunohistochemical studies have shown that, in
ﬁbrotic human or rat liver, portal and septal myoﬁbroblasts have
expression proﬁles different from those of interface myoﬁbroblasts
or sinusoidally located HSCs, suggesting that at least two subpopula-
tions of myoﬁbroblasts — HSC-derived myoﬁbroblasts (HSC-MFs)
and portal mesenchymal cell-derived myoﬁbroblasts (PMFs) —
populate the injured liver [17]. The possible contribution of
epithelial-to-mesenchymal transition to renal ﬁbrosis in vivo has
been challenged by studies based on genetic cell lineage tracing in
mice [18]. Likewise, studies based on genetic cell fate tracking have
strongly challenged the concept that either hepatocytes or
cholangiocytes acquire a mesenchymal phenotype in vivo through
epithelial-to-mesenchymal transition to produce the extracellular
matrix in liver ﬁbrosis [19–21]. A number of studies have also
suggested that circulating cells from the bone marrow can function
as stem cells, contributing to the liver myoﬁbroblast population
[22]. However, a recent study based on a system for the exclusive
detection of bone marrow-derived collagen-producing cells, showed
that bone marrow-derived cells played a limited role in collagen
production during liver ﬁbrosis [23].
3. Portal myoﬁbroblasts
In almost all types of chronic liver disease, including biliary
(i.e. primary biliary cirrhosis, biliary atresia), viral, alcoholic and
non-alcoholic fatty liver diseases, ﬁbrosis develops predominantly in
the portal area and appears to progress from this area, even if the
primary targets of injury are intralobular hepatocytes [24–28]. This
observation suggests that the contribution of PMFs to liver ﬁbrosis
may be more important than generally assumed. Furthermore, in
chronic liver diseases of various origins, including viral hepatitis and
non-alcoholic fatty liver disease, ﬁbrogenesis is associated with theoccurrence of a ductular reaction, in which duct-like cells with
progenitor features proliferate, expanding outwards from the
portal area. The correlation between the extents of the ductular
reaction and of replicative senescence in hepatocytes suggests that
ductular/progenitor cells may be recruited in situations in which
the regeneration of mature hepatocytes is impaired. One possible
explanation for this is that ductular/oval cells are less sensitive
to TGF-β-induced growth inhibition than hepatocytes [29]. Several
potential mechanisms by which cholangiocytes or hepatic progenitor
cells may promote ﬁbrogenesis (Fig. 1) have been reviewed
elsewhere [30] and new mechanisms have recently been put forward.
Ductular/progenitor cells may act on matrix accumulation directly,
through the release of tissue inhibitor metalloprotease 1 (TIMP1),
for example [31]. They may act on myoﬁbroblasts by releasing
promitogenic, proﬁbrogenic, chemotactic or anti-apoptotic factors.
Hepatic progenitor cells have been shown to increase hepatic
ﬁbrogenesis, in an experimental model in which rat liver ﬁbrosis is
induced by chronic treatment with a combination of carbon tetrachlo-
ride and acetylaminoﬂuorene, promoting activation of the hepatic
progenitor cell compartment [32]. Chronic treatment with carbon
tetrachloride alone caused liver ﬁbrosis, which began around the
central veins, eventually extending to form incomplete centro-central
septa with sparse ﬁbrogenic cells expressing α-smooth muscle actin.
In acetylaminoﬂuorene/carbon tetrachloride-treated animals, the
ﬁbrogenic response was strongly ampliﬁed and an expansion of the
subpopulation of hepatic progenitor cells expressing transforming
growth factor-β (TGF-β) was observed. In this model, hepatic
progenitor cells, through their production of TGF-β, contributed to the
accumulation of α-SMA-positive myoﬁbroblasts in the ductular
reaction, enhancing ﬁbrosis but also leading to disease progression and
a pattern of ﬁbrosis similar to that observed in humans. Furthermore,
ductular cells produce much more αvβ6 integrin than normal
cholangiocytes. This molecule is closely linked to periductal ﬁbrogenesis,
through the activation of TGF-β [33]. Ductular cells secrete growth
arrest-speciﬁc protein 6 (Gas6), which protects myoﬁbroblasts against
apoptosis [34]. A role for the hedgehog pathway in the interaction
between ductular cells and portal myoﬁbroblasts was also recently
highlighted. Both cell types producehedgehog ligands, thereby enhancing
each other's viability and proliferation, and the activation of this pathway
inmice ampliﬁes both the ductular and ﬁbrogenic responses triggered by
bile duct ligation [35]. Notch signaling is essential to the development of
tubular epithelial cells in the kidney, and activation of this pathway in
tubular cells has been implicated in renal ﬁbrosis [36]. Notch signaling is
also essential in biliary differentiation and has recently been shown to
be activated in rat experimental liver ﬁbrosis. In this context, high levels
of Notch3, Jagged1 (a Notch ligand) and Hes1 (a downstream target
gene) were observed and the blocking of Notch signaling activation by a
γ-secretase inhibitor signiﬁcantly attenuated portal ﬁbrosis [37]. In
Alagille syndrome, a disease caused by genetic defects of Notch signaling
and characterized by severe ductopenia, reactive ductular cells and
hepatic progenitor cells are very rare and liver ﬁbrosis ismuch less severe
than in biliary atresia, a disease in which an intense ductular reaction is
associatedwith rapid progression to biliary cirrhosis [38]. The importance
of the Notch pathway in liver ﬁbrosis has also been demonstrated in
double-heterozygousmicehaploinsufﬁcient for both Jagged1andanother
gene (Lunatic) altering ligand–receptor afﬁnity. In this model, intense
ductular proliferation contrasted with low levels of ﬁbrosis [39]. Finally,
hepatic progenitor cells have been shown to produce adipokines. In
pediatric non-alcoholic fatty liver disease, the degree of ﬁbrosis is related
to the production of resistin [28], an adipokine with proinﬂammatory
effects on HSCs [40] and hepatic progenitor cells.
No reliable markers have yet been identiﬁed for distinguishing
between HSCs and portal mesenchymal cells at the myoﬁbroblast
stage. We have established a culture model for PMFs obtained by
outgrowth from rat bile duct preparations [15]. These cells have
several features in common with rat liver myoﬁbroblasts [14,41]
Fig. 1. Interaction of ductular/hepatic progenitor cells with liver myoﬁbroblasts in wound healing. Ductular/hepatic progenitor cells bidirectionally interact with myoﬁbroblasts,
through multiple pathways, to proliferate and trigger proﬁbrogenic, proangiogenic and/or proregenerative actions, depending on their origin and microenvironment.
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procedures, and can be distinguished from HSC-MFs on the basis of
morphological criteria and growth behavior. Their myoﬁbroblastic
differentiation requires TGF-β and mechanical tension [41], and can
be triggered by PDGF-BB [41] or bile acids [42]. Following isolation
from normal rat liver and culture in the same conditions, HSC-MFs
are round, with an enlarged cytoplasm and poor survival after three
or four passages, whereas PMFs tend to be more elongated, with
more stress ﬁbers, and proliferate more strongly during multiple
passages [43]. Desmin production is differentially regulated, being
upregulated during activation in HSCs and shut down in portal
ﬁbroblasts. Staining for desmin might therefore be useful for
distinguishing between the two cell populations at the myoﬁbroblast
stage [15,16,41,44]. In two models of cholestatic liver injury induced
by bile duct ligation and hepatic arterial deprivation, ﬁbrosis involves
myoﬁbroblasts that are predominantly desmin-negative and, thus,
presumably, of portal origin [45]. In these models, HSCs undergo
massive early phenotypic changes, marked by increases in proliferation
and desmin overproduction [44,45], but only a minority of these cells
are converted into matrix-producing myoﬁbroblasts, which, after
prolonged injury, appear to circumscribe wounded hepatocytes to
form micronodules [45].
We investigated the relative contributions of PMFs and HSC-MFs
to various aspects of the liver wound-healing response, by comparing
these two cell populations at similar stages of myoﬁbroblastic
differentiation (i.e. with similar levels of α-SMA) in culture, by
comparative 2-DE MS/MS proteomic analysis [43]. We identiﬁed
proteins displaying differentially expression, all with myoﬁbroblast-
related functions, in PMFs. Phospho-coﬁlin, a small actin-binding
protein that accumulates during myoﬁbroblast differentiation and
promotes stress ﬁber formation and collagen contraction, was the
protein for which the difference in levels was the greatest. Most of
the proteins overproduced in HSC-MFs were involved in stress
responses, relating to hypoxic stress in particular, in keeping
with the interplay known to occur between interlobular hypoxia,
angiogenesis and ﬁbrogenesis in the liver [46]. The protein displaying
the highest level of overproduction in these cells was cytoglobin,
which is also known as stellate cell activation-associated protein
(STAP), a hypoxia-inducible hexacoordinated globin with reactive
oxygen species (ROS)-scavenging properties. In HSCs, cytoglobin isupregulated during myoﬁbroblastic differentiation [43,47] and
protects against oxidative stress and ﬁbrosis [48]. In this analysis,
we identiﬁed new potential markers in addition to those previously
identiﬁed as distinguishing between the two myoﬁbroblastic cell
populations (e.g. ﬁbulin 2 and Thy-1 cell surface antigen in PMFs;
reelin, cytoglobin, α2-macroglobin, mannan-binding lectin serine
peptidase 1 (MASP-1), glial ﬁbrillary acidic protein (GFAP) and
retinol-binding protein (RBP) in HSC-MFs (Table 1)). Overall these
and other ongoing studies suggest that both myoﬁbroblastic cell
types, each exposed to a particular microenvironment (hypoxia for
HSC-MFs, ductular reaction for PMFs), expand and carry out
specialist functions, in scarring and inﬂammation for PMFs, and in
vasoregulation and hepatocellular healing for HSC-MFs.
4. Myoﬁbroblasts in liver angiogenesis
Liver injury causes vascular disorganization and local tissue
hypoxia, which begins early in the course of disease [46]. Soon after
the induction of injury and long before the onset of cirrhosis
hypoxia-induced VEGF expression occurs, triggering angiogenesis, in
various experimental models [12,49,50]. An oxygen gradient is
established by unidirectional blood ﬂow from the portal vein and
hepatic artery to the central vein. Consequently, the periportal area
is less likely to undergo extreme oxygen deprivation than intralobular
areas. Interestingly, in a proteomic comparison of the two cell types,
we found that genes encoding proteins involved in the response to
hypoxia, such as cytoglobin, were more strongly expressed in
HSC-MFs than in PMFs. It has been suggested that HSC-MFs contrib-
ute to angiogenesis at the leading edge of ﬁbrotic septa [51].
Angiogenesis leads to the formation of new blood vessels from
pre-existing vessels. In chronic liver diseases, angiogenesis has
several major consequences: it contributes to portal hypertension
[52,53], aggravates ﬁbrosis [52,54–56] and promotes tumorigenesis
(review in [46]). The role of liver myoﬁbroblasts in angiogenesis has
been documented in the contexts of both cancer and ﬁbrosis.
Research on the angiogenic functions of myoﬁbroblasts has, to date,
focused on HSCs, but our personal unpublished data indicate that
portal mesenchymal cells also develop these functions. HSCs act as
liver pericytes for sinusoidal endothelial cells [5,57]. The two cell
types are found in close proximity and interactions between them
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transgenic zebraﬁsh model, in which HSCs were identiﬁed by the
presence of a basic helix–loop–helix transcription factor, revealed
that sinusoidal cells were required for the correct localization of
HSCs during development [58]. As mature liver pericytes, HSCs have
direct, physical interactions with endothelial cells and regulate
vascular development, stabilization, maturation and remodeling. HSCs
have been shown to develop focal adhesions (involving Ena/VASP
proteins), which promote angiogenesis [59]. HSCs also establish
paracrine interactions with endothelial cells. Once their differentiation
intomyoﬁbroblasts has been activated during ﬁbrogenesis, they secrete
proangiogenic cytokines: VEGF [12,49,51,60–62] and angiopoietin-1
[56,63] (Fig. 2). They also produce PDGF, a proﬁbrogenic factor that
also induces a proangiogenic phenotype in HSCs [64]. PDGF induces
angiopoietin production in HSCs [63]. Leptin, a circulating peptide
hormone produced by the adipose tissue, has also been shown to
induce the production of VEGF and angiopoietin-1 in HSCs in vitro
[60]. Intercellular communication may also occur through the release
of microparticles, which are transported in the bloodstream to act on
distant cells. HSCs can secrete microparticles containing Hedgehog
ligands able to modulate gene expression in endothelial cells [65].
Another important way in whichmyoﬁbroblasts promote angiogenesis
is the generation of hypoxia, through the production and deposition of
extracellular matrix. Hypoxia induces the HIF-dependent expression
of VEGF in hepatocytes and of VEGF, angiopoietin-1 and their respective
receptors in HSCs [51].
Newly formed blood vessels can supply tissues with proinﬂammatory
cytokines from the local and systemic circulation. These cytokines
maintain chronic inﬂammation in the liver, leading to ﬁbrosis. This
ﬁbrosis leads to angiogenesis, which in turn causesmore ﬁbrosis, thereby
establishing a vicious circle. Angiogenesis can also lead to an increase in
interstitial ﬂuid ﬂow, because newly formed vessels may be leaky before
their stabilization. This interstitial ﬂuid ﬂow induces myoﬁbroblast
differentiation [66]. Finally, endothelial cells from newly formed vessels
may have paracrine effects on myoﬁbroblasts (see Fig. 2). Changes of
endothelial cells during angiogenesis may disrupt the subtle balance
between endothelial cells and pericytes. For instance, differentiated
sinusoidal endothelial cells promote the reversion of HSCs to a
quiescent state, whereas capillarized sinusoidal endothelial cells do not
[67]. Proangiogenic cytokines also have proﬁbrogenic effects on
myoﬁbroblasts. The HSC migration induced by hypoxia is mediated by
VEGF [68]. VEGF increases proliferation, extracellular matrix deposition
andmigration in HSCs [12,51,55,62,69]. The exposure of HSCs to placenta
growth factor activates the ERK pathway, and increases migration,Table 1
Previously published proposed markers of hepatic stellate cell-derived myoﬁbroblasts
(HSC-MFs) and portal myoﬁbroblasts (PMFs).
Name (references)
HSC-MFs Reelin [91]
Cytoglobin [43]
α-2-macroglobulin [14]
Desmin [14]
Vascular cell adhesion molecule 1 [14]
Mannan-binding lectin serine peptidase [14]
Glial ﬁbrillary acidic protein [14,17]
Pirin (iron-binding nuclear protein) [43]
Protein disulﬁde isomerase family A, member 4 [43]
Neural cell adhesion molecule 1 [14,17]
Retinol binding protein 1, cellular [92]
PMFs Fibulin 2 [14]
Thy-1 cell surface antigen[93]
Fibronectin 1 [14]
N CAM[17]
Gremlin [93,94]
Heat shock protein 1 [43]
Latexin [43]
Coﬁlin 1, non-muscle [43]proliferation and cytoskeleton remodeling [70]. Neuropilin-1 (VEGF
co-receptor) increases HSC migration [71].
5. Myoﬁbroblasts in liver regeneration
Liver regeneration induced by partial hepatectomy, a model of
normal liver tissue repair, is associated with myoﬁbroblastic changes of
HSCs, including the loss of vitamin A content and the upregulation of
markers such as α-SMA, IL-6 and hepatocyte growth factor [72]. This
suggests that HSCs undergoing myoﬁbroblastic differentiation are
involved in a regenerative response. Myoﬁbroblastic HSCs can support
hepatocellular regeneration through the release of mitogens, such as
hepatocyte growth factor, pleiotrophin or epimorphin, and induction of
the delta-like 1 homolog [73]. It has also been shown that Foxf1
(a mesenchyme-speciﬁc transcription factor) haploinsufﬁciency in mice,
caused a defect in the myoﬁbroblastic differentiation of HSCs, resulting
in abnormal liver regeneration [74]. However, HSCs have also been
reported to be negative regulators of hepatocyte regeneration. In one
study, this negative regulatory function was attributed to stimulation of
the 5-hydroxytryptamine 2B receptor on HSCs by serotonin, which
activates the expression of TGF-β1, a powerful suppressor of hepatocyte
proliferation [75]. In another study, HSC depletion was achieved in
ganciclovir-treated transgenic mice expressing the herpes simplex
virus-thymidine kinase gene driven by the mouse GFAP promoter.
HSC depletion was associated with a marked attenuation of ﬁbrosis
and liver injury, in the carbon tetrachloride and bile duct ligation
models, suggesting that activated HSCs ampliﬁed liver damage [76].
Hepatocellular stellate cell crosstalk can also drive progression in
hepatocellular carcinoma, by generating a permissive inﬂammatory and
proangiogenicmicroenvironment, in particular [77]. Livermyoﬁbroblasts,
probably of portal origin, interact with the ductular/progenitor cells to
promote their survival and proliferation via the hedgehog pathway
[35] and loss of the ectonucleotidase NTPDase2, an antiproliferative factor
expressed in normal ﬁbroblasts [78]. Production of the Notch ligand
Jagged 1 by myoﬁbroblasts promotes the biliary speciﬁcation of hepatic
progenitor cells, directing their differentiation into cholangiocytes [79].
Myoﬁbroblast-derived PDGF-BB also promotes survival signaling in
cholangiocarcinoma cells [80].
6. Deactivation of liver myoﬁbroblasts
The deactivation of myoﬁbroblasts is critical for the termination
of the reparative response and the restoration of normal tissue
structure. It is generally assumed that terminally differentiated
myoﬁbroblasts undergo apoptosis when ﬁbrosis regresses. Indeed,
some myoﬁbroblasts have been observed to undergo apoptosis [81] or
senescence [82] during the regression of liver ﬁbrosis. Inmyoﬁbroblasts
derived from human lung ﬁbroblast cells continuously stimulated with
serum, α-SMA levels have been shown to decrease with increasing cell
proliferation [83]. These changes, interpreted as dedifferentiation, are
associated with the downregulation of MyoD, a basic helix–loop–helix
transcription factor with a critical function in myogenic differentiation
and in TGF-β1-induced myoﬁbroblast differentiation [83]. It has been
shown, with a hydrogel system, that the substrate modulus of valvular
myoﬁbroblasts can be decreased, leading to their deactivation and
decreases in the levels of α-SMA stress ﬁbers and proliferation,
these cells then being redirected to become dormant ﬁbroblasts [84].
Likewise, changes in substrate stiffness have been shown to induce
a reversion of the myoﬁbroblastic phenotype in human liver
myoﬁbroblasts [85]. Culture studies have suggested that myoﬁbroblastic
HSCs may revert to a more quiescent phenotype, characterized by the
loss of ﬁbrogenic genes and the expression of adipogenic genes
[86]. The cre-loxP-based genetic labeling of myoﬁbroblasts has been
used to show that, during recovery from carbon tetrachloride or
alcohol-induced liver ﬁbrosis, myoﬁbroblastic stellate cells may revert to
an inactive, although not entirely quiescent phenotype, with the capacity
Fig. 2.Myoﬁbroblastic changes of hepatic stellate cells related to sinusoidal remodeling and angiogenesis in the ﬁbrotic liver. In the ﬁbrotic liver, an increasing number of HSCs wrap
around sinusoids, thereby contributing to the formation of a high-resistance, constricted sinusoidal vessel. At the cellular level, a number of soluble factors are involved in this pro-
cess, through autocrine and paracrine signaling between HSC-MFs and sinusoidal endothelial cells.
Reproduced with permission from Thabut & Shah, J Hepatol 2010 [95].
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another study, the authors used single-cell PCR and genetic cell fate
tracking to show that about half the HSCs were deactivated, with
decreases in α-SMA and collagen I levels, after the cessation of carbon
tetrachloride treatment in mice. The deactivated HSCs obtained in this
model were also more responsive to proﬁbrogenic stimulation than
fully quiescent HSCs [88]. In patients with chronic hepatitis C and a
sustained virological response (SVR), the analysis of paired pre- and
post-treatment liver biopsies showed that treatment led to the regression
of cirrhosis and a decrease in collagen content in most cases. Ductular
proliferation also decreased, but sinusoidal capillarization persisted, as
assessed by analyses of CD34andα-SMA, suggesting that thedeactivation
of HSCswas only partial [89]. However, in this study,α-SMA levels either
remained unchanged or increased, despite the regression of ﬁbrosis,
suggesting that myoﬁbroblastic differentiation may be irreversible once
it has progressed beyond a certain stage. Alternatively, it may depend
on themicroenvironment, a scenario supported by the fact that activated
HSCs revert to quiescencewhen coculturedwith differentiated sinusoidal
endothelial cells, but notwith capillarized cells [67]. In addition, the fate of
portal myoﬁbroblasts needs to be addressed, to clarify the mechanisms
underlying ﬁbrosis progression. The triggering ofmyoﬁbroblast apoptosis
by pharmacological [90] or genetic [87] approaches could potentially
improve treatment, by causing ﬁbrosis regression. Partial reversion of
the myoﬁbroblastic phenotype may also lead to a favorable outcome,
but a potential threat remains in cases of subsequent injury. Complete
reversion to a quiescent phenotype is clearly the ultimate goal of
treatment, but it may be possible to achieve such reversion only in the
early stages of disease.7. Conclusions
At least two populations of liver myoﬁbroblasts, derived from
portal mesenchymal cells and hepatic stellate cells, accumulate in
the injured liver. We propose a model of liver tissue repair, in
which both myoﬁbroblastic populations, each exposed to a different
microenvironment, expand and carry out specialist functions, in
scarring for PMFs and hepatocellular healing for HSC-MFs. These
speciﬁc features should be taken into account in the development of
antiﬁbrotic drugs, to ensure the targeting of collagen cross-linking
or of fully differentiated myoﬁbroblasts, rather than stages of
myoﬁbroblastic differentiation, which may be beneﬁcial for the
regeneration of liver epithelial cells. Strategies for restoring the
normal, quiescent phenotype of myoﬁbroblast precursors should
also be considered.Acknowledgements
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